Here, we not only corroborate prior findings of clinically relevant, elevated levels of CXCL9 and CXCL10 in JDM patients, but we also demonstrate that their gene expression and production can be induced in vitro using human bioengineered myobundles. Here, CXCL10 is linked to juvenile dermatomyositis.